Ignite Creation Date:
2024-05-06 @ 8:20 AM
Last Modification Date:
2024-10-26 @ 11:58 AM
Study NCT ID:
NCT02714790
Status:
COMPLETED
Last Update Posted:
2016-03-23
First Post:
2016-03-03
Brief Title:
Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia
Sponsor:
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Organization:
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Study Overview
Official Title:
Ruolo Prognostico Della Malattia Minima Residua Nella Leucemia Mieloide Acuta
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LAM-MMR
Brief Summary:
Study purpose is to assess the prognostic role of Minimal Residual Disease defined as medullary expression of WT1 gene performed at Baseline and during treatment according to clinical practice MRD results will be relate to treatment outcome and survival analysis variables Overall Survival Disease Free Survival Cumulative Incidence of Relapse
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None